Similar articles

• SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

  Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. Fong TA, et al. Cancer Res. 1999 Jan 1;59(1):99-106. Cancer Res. 1999. PMID: 9892193
• Angiogenesis inhibition in solid tumors.

  Rosen LS. Rosen LS. Cancer J. 2001 Nov-Dec;7 Suppl 3:S120-8. Cancer J. 2001. PMID: 11779082 Review.
• Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival.

  Takamoto T, Sasaki M, Kuno T, Tamaki N. Takamoto T, et al. Kobe J Med Sci. 2001 Aug;47(4):181-91. Kobe J Med Sci. 2001. PMID: 11733657
• Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

  Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM. Mendel DB, et al. Anticancer Drug Des. 2000 Feb;15(1):29-41. Anticancer Drug Des. 2000. PMID: 10888034 Review.
• Technology evaluation: IMC-1C11, ImClone Systems.

  Hunt S. Hunt S. Curr Opin Mol Ther. 2001 Aug;3(4):418-24. Curr Opin Mol Ther. 2001. PMID: 11525567 Clinical Trial.